Your Health, We Care
Coadministration of Tazemetostat with a strong or moderate CYP3A inhibitor increases tazemetostat plasma concentrations, which may increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with Tazemetostat. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce Tazemetostat dose.
Coadministration of Tazemetostat with a strong CYP3A inducer decreases tazemetostat plasma concentrations, and coadministration of Tazemetostat with a moderate CYP3A inducer may also decrease tazemetostat plasma concentrations. The decrease in tazemetostat plasma concentration may decrease the efficacy of Tazemetostat. Avoid coadministration of moderate or strong CYP3A inducers with Tazemetostat.
Coadministration of Tazemetostat with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.
from FDA，2024.08
